Teams link: Join the Meeting Now

Meeting ID: 234 297 242 669 890

Passcode: EG2uo7X8

Learning Objectives: 

  • Summarize current treatment strategies and clinical outcomes in pancreatic adenocarcinoma to contextualize the role of emerging therapies

  • Evaluate the efficacy and safety of daraxonrasib in the RASolute-302 trial and its impact on metastatic pancreatic cancer management

  • Develop a practical approach to daraxonrasib selection, toxicity management, and implementation in patients with pancreatic adenocarcinoma 

Session date: 
10/01/2026 - 2:00pm to 3:00pm CDT
Location: 
In-person and Virtually
Will be determined by room availability
600 Highland Ave
Madison, WI 53705
United States
See map: Google Maps
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
Add to calendar: 
Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Tyler Philipps